2023-03-31T07:03:21-05:00 2022-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2021-07-01 231907729 JDRF INTERNATIONAL JDRF 8005332873 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 ROBERT KING CFAO 2124797550 2023-03-29 1 ROBERT KING 999009999 DEVIN L DUNCAN P01249521 2127589700 2023-03-28 3 AAL1 IAL1 2021 2023-04-26 12:10:37Z AARON KOWALSKI 200 VESEY STREET NEW YORK NY 10281 379709090 0 X WWW.JDRF.ORG X 1970 PA IMPROVING LIVES BY ACCELERATING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D. SEE SCHEDULE O. 15 14 496 235000 96472 72762 190647071 205076492 0 20503582 28497433 10283819 3878139 2731612 223022643 238595505 28823131 72152705 0 0 53217471 57146058 46678 1388063 28287437 33383167 32202373 115470447 162889199 107552196 75706306 361315226 389461665 100761301 94551427 260553925 294910238 X SEE SCHEDULE O. 0 0 72152705 72152705 RESEARCH FUNDING - FOR THE FY2022 PERIOD ENDING JUNE 30, 2022, JDRF DIRECTLY FUNDED RESEARCH GRANTS AND INDUSTRY AGREEMENTS FOR WHICH $70 MILLION IN RESEARCH GRANT EXPENSE, NET WAS RECOGNIZED ACCORDING TO GAAP AND EXCLUDING $11.8 MILLION OF PROGRAMMATIC RESEARCH INVESTMENTS THAT ARE RECORDED ON THE ORGANIZATION'S BALANCE SHEET. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING, SEE SCHEDULE O. 36669581 RESEARCH SUPPORT - JDRF MAINTAINS AN IN-HOUSE TEAM OF SKILLEDSCIENTIFIC, MEDICAL, POLICY AND GOVERNMENT RELATIONS PROFESSIONALSWHO PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE EVALUATIONOF RESEARCH FUNDING OPPORTUNITIES BY JDRF AND INFLUENCING RESEARCHDIRECTION AND THE DISBURSEMENT OF RESEARCH FUNDS FROM OTHERS.THESE PROFESSIONALS ALSO WORK WITH REGULATORY AND POLICY OFFICIALSTO ENSURE THAT RESEARCH CAN PROCEED WITHOUT DELAY AND RESULTS AREUNDERSTOOD BY HEALTHCARE DECISION MAKERS. FOR AN EXPANDEDDESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO RESEARCHSUPPORT, SEE SCHEDULE O. 13713654 PUBLIC EDUCATION AND OUTREACH - JDRF EDUCATES THE COMMUNITY AND PROVIDES OUTREACH SERVICES TO NEWLY DIAGNOSED CHILDREN AND ADULTS, THEIR FAMILIES, AND OTHERS ABOUT TYPE 1 DIABETES (T1D) AND ITS COMPLICATIONS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION AND OUTREACH, SEE SCHEDULE O. 122535940 1 1 0 1 0 0 0 0 0 1 1 0 1 0 1 1 0 1 0 1 1 1 0 1 1 1 0 1 0 1 0 0 0 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 1 227 3 1 496 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 X 15 14 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VT VA WA WV WI WY X X ROBERT KING 8005332873 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 JOE LACHER CHAIR OF THE BOARD 5.00 0.00 X X 0 0 0 LISA WALLACK VICE CHAIR OF THE BOARD 5.00 0.00 X X 0 0 0 MICHAEL ALTER CHAIR, FUNDING COMMITTEE 5.00 0.00 X 0 0 0 GRANT BEARD CHAIR, AUDIT & RISK COMMITTEE 5.00 0.00 X 0 0 0 ELIZABETH CASWELL BOARD MEMBER 5.00 0.00 X 0 0 0 STEVEN DAVIS CHAIR NOMINATING & GOV COMMITTEE 5.00 0.00 X 0 0 0 CLAUDIA GRAHAM PHD BOARD MEMBER 3.00 0.00 X 0 0 0 PAUL HEATH CHAIR, ADVOCACY & IMPACT COMMITTEE 5.00 0.00 X 0 0 0 KAREN JORDAN CHAIR, RESEARCH COMMITTEE 5.00 0.00 X 0 0 0 JEFF PLUMER CHAIR, TALENT & COMP. COMMITTEE 5.00 0.00 X 0 0 0 JENNIFER SCHNEIDER MD BOARD MEMBER 3.00 0.00 X 0 0 0 CHRISTOPHER TURNER CHAIR, FINANCE & INVEST. COMM 5.00 0.00 X 0 0 0 MATT VAREY BOARD MEMBER 3.00 0.00 X 0 0 0 DRAYTON VIRKLER BOARD MEMBER 3.00 0.00 X 0 0 0 KAREY L WITTY BOARD MEMBER 3.00 0.00 X 0 0 0 AARON KOWALSKI PHD CHIEF EXECUTIVE OFFICER 50.00 0.00 X 751382 0 71994 TIMOTHY DOYLE COO/PRESIDENT/ASST TREAS (BEG 12/21) 50.00 0.00 X 544030 0 56100 ANNE GEHRING CONTRACT CFO (BEG 5/21, END 10/21) 50.00 0.00 X 174363 0 0 ROBERT KING CFAO/TREASURER (BEG 10/21) 50.00 0.00 X 81324 0 5975 TROY LINDLOFF CDO/ASST. TREASURER (END 11/21) 50.00 0.00 X 500110 0 17699 JAMES MCDONALD BOARD LIAISON/SECRETARY 50.00 0.00 X 125218 0 6797 SYDNEY YOVIC CHIEF OF STAFF/ASSISTANT SECRETARY 50.00 0.00 X 259812 0 44411 SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 50.00 0.00 X 345769 0 20465 STEVEN ST PETER MANAGING DIRECTOR, T1D FUND 50.00 0.00 X 712891 0 38127 HELEN ELLIAS MANAGING DIRECTOR, T1D FUND 50.00 0.00 X 529668 0 63779 CRAIG ROBERTSON VP, FIELD DEVELOPMENT 50.00 0.00 X 310533 0 31277 CYNTHIA RICE CHIEF MISSION OFFICER 50.00 0.00 X 347838 0 39881 GILLIAN GREEN VP LEADERSHIP GIVING 50.00 0.00 X 303511 0 47676 YURY KUKUSHKIN MANAGING DIRECTOR, T1D FUND 50.00 0.00 X 310631 0 15183 SRINIVAS MISHRA CHIEF TECH OFFICER (END 8/21) 50.00 0.00 X 245705 0 28010 JOANNE MARTZ CFO/TREASURER (END 5/21) 50.00 0.00 X 348691 0 24485 5891476 0 511859 151 1 1 0 INNOVATION CLOUD LLC 356 OSWEGO CT WEST NEW YORK NJ 07093 IT CONSULTING 2476956 THE PURSUANT GROUP 15660 DALLAS PKWY SUITE 1000 DALLAS TX 75248 FUNDRAISING AND MARKETING 1681088 KAVYOS CONSULTING INC 485 C ROUTE 1 SOUTH SUITE 320 ISELIN NJ 08830 IT CONSULTING 1223483 BLACKBAUD INC 65 FAIRCHILD STREET CHARLESTON SC 29492 SOFTWARE SERVICES 1199682 BLUE STATE DIGITAL 41 FLATBUSH AVENUE BROOKLYN NY 11217 FUNDRAISING AND MARKETING 1162384 57 2943084 99817013 102316395 5611770 205076492 PROGRAM RELATED INVEST 541714 20503582 20503582 20503582 2775930 96472 2679458 131868601 124360712 7507889 7507889 7507889 16742873 99817013 16742873 0 738140 10000 728140 728140 GRANT REFUNDS & ADJUST 813212 1617037 1617037 MISC REVENUE 900099 386435 386435 2003472 238595505 0 96472 33422541 49414448 49414448 22738257 22738257 4545719 2956133 695654 893932 60386 60386 42629011 24403950 5239227 12985834 1186454 691504 135454 359496 5977931 3452490 673880 1851561 2746557 1586689 350579 809289 470275 307693 43336 119246 217925 217925 127123 127123 1388063 1388063 440890 440890 2743072 937007 916000 890065 2026369 850270 129624 1046475 767097 456647 83796 226654 5936467 3461593 684689 1790185 4913003 2830110 574400 1508493 839275 453886 74842 310547 498654 195785 58077 244792 2556 1427 322 807 6330959 3652269 758536 1920154 556782 227239 189257 140286 OUTREACH EXPENSES 4161874 3226293 637086 298495 FUNDRAISING POSTAGE & P 1278245 1278245 DUES, FEES, & SUB 665413 366540 136613 162260 OTHER 226394 138201 25635 62558 162889199 122535940 12065822 28287437 26785629 34312094 19599908 4006288 51322172 56535885 3785572 2438959 0 0 0 0 3450000 2218711 0 0 6454865 15358433 25368692 14797623 11818148 10571069 174011783 212935519 748528 533309 63338621 50551398 0 361315226 389461665 23190389 17575122 61750136 69409827 13236673 5150523 2584103 2415955 100761301 94551427 X 193001095 229545554 67552830 65364684 260553925 294910238 361315226 389461665 75706306 -41349993 0 X 0 1 X 1 0 X 219968105 215659011 194074339 190647071 203302047 1023650573 219968105 215659011 194074339 190647071 203302047 1023650573 716203 1022934370 1309523 2439225 2918738 2297884 2679851 11645221 138747 186965 29579 58494 96079 509864 1793044 2313482 1671720 3345522 22507054 31630822 1067436480 0.95830 0.98140 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2017 AMOUNT: $ 1,793,044. 2018 AMOUNT: $ 2,313,482. 2019 AMOUNT: $ 1,671,720. 2020 AMOUNT: $ 3,345,522. 2021 AMOUNT: $ 22,507,054. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 1 11440 0 1 3990 1 215517 0 0 230947 0 PART II-B, LINE 1: GENERAL STATEMENT OF ACTIVITIES JDRF IS THE LEADING GLOBAL ORGANIZATION FUNDING TYPE 1 DIABETES (T1D) RESEARCH, FOCUSED ON CURING T1D AND IMPROVING LIVES. JDRF'S ADVOCACY INCLUDES LOBBYING ACTIVITY TO ENSURE CONGRESS CONTINUES TO INVEST IN CRITICALLY IMPORTANT MEDICAL RESEARCH AND PUTS IN PLACE POLICIES TO ADVANCE DEVELOPMENT AND ACCESS TO THERAPIES TO CURE T1D AND HELP PEOPLE STAY AS HEALTHY AS POSSIBLE UNTIL THAT DAY. JDRF HAS BEEN INSTRUMENTAL IN SECURING THE RENEWAL OF THE SPECIAL DIABETES PROGRAM, WHICH PROVIDES $150M ANNUALLY FOR T1D RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH. JDRF STAFF AND VOLUNTEERS COMMUNICATE WITH GOVERNMENT OFFICIALS THROUGH EMAIL, PHONE CALLS, AND MEETINGS, TO EDUCATE THEM ON ISSUES AND ENCOURAGE THE ADVANCEMENT OF LEGISLATION. 8911983 25000 -1144983 207917 7584083 7709169 2111094 908280 8911983 7887833 -140727 33086 71023 7709169 7567601 221441 102034 3243 7887833 7341367 268304 42070 7567601 0.00000 1.00000 0.00000 0 0 1009931 203913 806018 24358761 14593710 9765051 10571069 T1D FUND PROGRAM RELATED INVESTMENT 50551398 F 50551398 SPLIT INTEREST CHARITABLE RMDR TRUST 2415955 2415955 X 195729918 -41349993 542333 -1617037 -42424697 238154615 440890 440890 238595505 161373605 542333 -1617037 -1074704 162448309 440890 440890 162889199 PART V, LINE 4: ORGANIZATION'S ENDOWMENT FUNDS THE ORGANIZATION UTILIZES EARNINGS ON ENDOWMENT FUNDS IN THE MANNER SPECIFIED BY THE DONOR AND/OR FOR SUPPORTING THE ORGANIZATION'S GENERAL EXEMPT PURPOSE. PART X, LINE 2: UNCERTAIN TAX POSITIONS JDRF IS A NOT-FOR-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND IS ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA. THE EFFECT OF INCOME TAX POSITIONS IS RECOGNIZED ONLY IF THE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO JDRF'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. UNRELATED BUSINESS INCOME TAX LIABILITY WAS INSIGNIFICANT FOR THE YEARS ENDING JUNE 30, 2022 AND 2021. 1 EAST ASIA AND THE PACIFIC GRANTMAKING RESEARCH GRANTS 5016705 NORTH AMERICA GRANTMAKING RESEARCH GRANTS 3825650 EUROPE GRANTMAKING RESEARCH GRANTS 11420906 MIDDLE EAST AND NORTH AFRICA GRANTMAKING RESEARCH GRANTS 2274996 SOUTH ASIA GRANTMAKING RESEARCH GRANTS 200000 EUROPE 2 PROGRAM SERVICES RESEARCH SUPPORT 294361 EUROPE INVESTMENTS INVESTMENTS 3431835 NORTH AMERICA INVESTMENTS INVESTMENTS 3020423 0 2 0 0 0 2 29484876 0 29484876 EUROPE (INCLUDING ICELAND AND GREENLAND) METABOLIC CONTROL 81635 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 50000 CHECK/WIRE TRANSFER 0 N/A N/A SOUTH ASIA METABOLIC CONTROL 200000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 917181 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA PREVENTION 297815 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC MISSION 800000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) TRANSPORTFOLIO 56330 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) TRANSPORTFOLIO 94418 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC IMMUNOTHERAPIES 109278 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 366430 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REGENERATION 325000 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA COMPLICATIONS 360000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 149963 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA METABOLIC CONTROL 100967 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 218660 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 126500 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 499448 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) TRANSPORTFOLIO 465000 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA TRANSPORTFOLIO 833060 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) METABOLIC CONTROL 2024922 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 609520 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 51477 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) METABOLIC CONTROL 100000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA ARTIFICIAL PANCREAS 336087 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REPLACEMENT 54419 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 99928 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC IMMUNOTHERAPIES 300000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC BETA CELL REGENERATION 109919 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC IMMUNOTHERAPIES 100000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PSYCHOSOCIAL 574929 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 424616 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA ARTIFICIAL PANCREAS 156936 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC BETA CELL REPLACEMENT 95100 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA PREVENTION 775000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 181160 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA PREVENTION 150000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 374927 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC IMMUNOTHERAPIES 1635568 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 162520 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 410000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 497585 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA PSYCHOSOCIAL 566484 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC COMPLICATIONS 499999 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC PREVENTION 38837 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REPLACEMENT 647599 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 349264 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) COMPLICATIONS 117473 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 262535 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) COMPLICATIONS 472642 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 1012196 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) METABOLIC CONTROL 200816 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 70000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC PREVENTION 289620 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 900000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REPLACEMENT 60038 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA ARTIFICIAL PANCREAS 423091 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 63131 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 399851 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC PREVENTION 296077 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) ARTIFICIAL PANCREAS 50000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC METABOLIC CONTROL 742308 CHECK/WIRE TRANSFER 0 N/A N/A 0 61 1 0 1 1 0 1 PART I, LINE 2: GRANT MONITORING PROCEDURES RESEARCH GRANTS ARE AWARDED BY JDRF INTERNATIONAL ("JDRFI") WITH THE SUPPORT OF JDRFI'S RESEARCH COMMITTEE COMPRISED OF "JDRFI BOARD MEMBERS AND OTHER VOLUNTEERS" FOLLOWING THE RECOMMENDATIONS OF AN IN-HOUSE TEAM OF PROFESSIONAL SCIENTIFIC STAFF AND WITH INPUT FROM EXTERNAL SCIENTIFIC REVIEWERS. THE REVIEW PROCESS INCLUDES THE FOLLOWING CRITERIA: (1) THE SCIENTIFIC MERIT OF THE PROPOSED RESEARCH OUTLINED IN A GRANT APPLICATION AND (2) THE RELATIONSHIP OF THE PROPOSED RESEARCH TO JDRF'S GOAL TO IMPROVE LIVES TODAY AND TOMORROW BY ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D AND ITS COMPLICATIONS. THE SCIENTIFIC RESEARCH TEAM AND GRANT ADMINISTRATION STAFF MAINTAIN CLOSE CONTACT WITH GRANTEES, PROVIDING ADVICE AND EVALUATION, REVIEWING PROGRESS REPORTS, REVIEWING RESEARCH EXPENDITURES VERSUS AGREED BUDGETS, AND HELPING DISSEMINATE RESEARCH RESULTS. PART III ACCOUNTING METHOD: PART II, LINES 2 AND 3: WHILE MANY FOREIGN GRANTEES MAY BE RECOGNIZED AS CHARITIES IN THEIR RESPECTIVE COUNTRY OR AS 501(C)(3) ORGANIZATIONS BY THE IRS, JDRF DOES NOT HAVE A FEASIBLE WAY TO VALIDATE FOREIGN TAX EXEMPTION AND CONSERVATIVELY CLASSIFIES ALL FOREIGN GRANTS AS OTHER. X X X X X 1 BLUE STATE DIGITAL 41 FLATBUSH AVENUE 8TH FL BROOKLYN NY 11217 DIRECT APPEAL FUNDRAISING SERVICES 0 4397672 747732 3649940 THE PURSUANT GROUP 15660 NORTH DALLAS PARKWAY SUITE 1 DALLAS TX 75248 DIRECT APPEAL FUNDRAISING SERVICES 0 2651598 495200 2156398 CARS (CHARITABLE ADULT RIDES AND SERVICES) 4669 MURPHY CANYON RD 200 SAN DIEGO CA 92123 CAR DONATION 1 186460 33140 153320 CASWELL ZACHRY GRIZZARD 6301 GASTON AVENUE SUITE 715 DALLAS TX 75214 PLANNED GIVING MARKETING 0 10000 111991 -101991 7245730 1388063 5857667 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI ILLINOIS GALA 15021026 14079351 941675 0 137885 298546 372611 132633 S. TEXAS BALL 2872927 2294620 578307 0 4383 239681 231208 103035 290 98665933 83443042 15222891 0 2549670 2740998 3774565 6157658 116559886 99817013 16742873 2691938 3279225 4378384 6393326 16742873 0 738140 10000 0 0 738140 10000 10000 728140 AL AK AZ CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI 1 0 0 0 1.00000 KIMBERLY ZINGALE MANAGER FINANCIAL REPORTING AND COMPLIANCE - JDRF 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 0 ROBERT KING CFO - JDRF FILING GAMING APPLICATIONS AND REPORTS X 0 PART I, LINE 2: CHARITABLE ADULT RIDES AND SERVICES (CARS) IS A THIRD-PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS DONATED TO JDRF. DONORS CALL A TOLL-FREE NUMBER AND ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, CARS HANDLES ALL IRS 1098-C REPORTING. CARS WITHHELD $20,763 FROM THE GROSS SALES FOR VARIOUS SELLING EXPENSES. JDRF PAID FUNDRAISING EXPENSES OF $383,046 FOR POSTAGE AND $866,254 FOR PRINTING TO THE PURSUANT GROUP. THE INVOICES PROVIDE AN ITEMIZED LIST OF SERVICES AND EXPENSES. JDRF PAID FUNDRAISING EXPENSES OF $28,946 FOR POSTAGE TO CASWELL. THE INVOICES PROVIDE AN ITEMIZED LIST OF SERVICES AND EXPENSES. 1 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX NY 10461 830621846 501(C)(3) 980547 0 N/A N/A PSYCHOSOCIAL AVERA MCKENNAN 1325 S CLIFF AVENUE SIOUX FALLS SD 57108 301043916 501(C)(3) 2480110 0 N/A N/A PSYCHOSOCIAL BAYLOR COLLEGE OF MEDICINE PO BOX 301207 DALLAS TX 753031207 741613878 501(C)(3) 64999 0 N/A N/A PSYCHOSOCIAL BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE RD DUARTE CA 91010 953432210 501(C)(3) 395153 0 N/A N/A BETA CELL REGENERATION BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE RD DUARTE CA 91010 953432210 501(C)(3) 300000 0 N/A N/A BETA CELL REPLACEMENT BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE RD DUARTE CA 91010 953432210 501(C)(3) 300000 0 N/A N/A IMMUNOTHERAPIES BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE RD DUARTE CA 91010 953432210 501(C)(3) 66000 0 N/A N/A TRANSPORTFOLIO BETH ISRAEL DEACONESS MEDICAL CENTER INC 330 BROOKLINE AVE BOSTON MA 02215 042103881 501(C)(3) 110000 0 N/A N/A IMMUNOTHERAPIES BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 595000 0 N/A N/A BETA CELL REPLACEMENT BOSTON COLLEGE 140 COMMONWEALTH AVENUE CHESTNUT HILL MA 02467 042103545 501(C)(3) 110000 0 N/A N/A IMMUNOTHERAPIES BROWN UNIVERSITY 164 ANGELL STREET-BOX 1929 PROVIDENCE RI 02912 050258809 501(C)(3) 515513 0 N/A N/A BETA CELL REPLACEMENT CARNEGIE MELLON UNIVERSITY PO BOX 371032 PITTSBURGH PA 15213 250969449 501(C)(3) 249996 0 N/A N/A BETA CELL REPLACEMENT CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVE STE 357 CLEVELAND OH 44106 341018992 501(C)(3) 200000 0 N/A N/A IMMUNOTHERAPIES CHILDREN'S HOSPITAL OF PHILADELPHIA 3401 CIVIC CENTER BLVD ABRAMSON RESEARCH CENTER PHILADELPHIA PA 19104 231352166 501(C)(3) 150000 0 N/A N/A PREVENTION CIVICA RX 2912 W EXECUTIVE PKWY STE 325 LEHI UT 840434622 844514428 501(C)(3) 3000000 0 N/A N/A MISSION COLORADO SCHOOL OF MINES 1500 ILLINOIS ST GOLDEN CO 80401 846000551 501(C)(3) 110000 0 N/A N/A BETA CELL REGENERATION CORNELL UNIVERSITY 373 PINE TREE RD CORNELL UNIVERSITY ITHACA NY 14850 150532082 501(C)(3) 110000 0 N/A N/A BETA CELL REPLACEMENT CRITICAL PATH INSTITUTE (C-PATH) 1730 EAST RIVER ROAD 200 TUCSON AZ 85718 201991334 501(C)(3) 266757 0 N/A N/A IMMUNOTHERAPIES DUKE UNIVERSITY PO BOX 602651 CHARLOTTE NC 282602651 560532129 501(C)(3) 65683 0 N/A N/A METABOLIC CONTROL DUKE UNIVERSITY PO BOX 602651 CHARLOTTE NC 282602651 560532129 501(C)(3) 519452 0 N/A N/A PSYCHOSOCIAL ENABLE BIOSCIENCES INC 953 INDIANA ST SAN FRANCISCO CA 94107 474916653 N/A 114000 0 N/A N/A PREVENTION GEISINGER CLINIC 100 N ACADEMY AVE DANVILLE PA 17822 236291113 501(C)(3) 495711 0 N/A N/A PREVENTION GEORGIA TECH RESEARCH CORPORATION PO BOX 100117 ATLANTA GA 30384 580603146 501(C)(3) 136904 0 N/A N/A BETA CELL REPLACEMENT GINER INC 89 RUMFORD AVE NEWTON MA 02466 042529800 N/A 19984 0 N/A N/A BETA CELL REPLACEMENT ILLINOIS INSTITUTE OF TECHNOLOGY IIT GRANTS LOCKBOX 777562 7562 SOLUTION CENTER CHICAGO IL 606777005 362170136 501(C)(3) 94500 0 N/A N/A ARTIFICIAL PANCREAS INDIANA BIOSCIENCES RESEARCH INSTITUTE 1210 WATERWAY BLVD STE 2000 INDIANAPOLIS IN 46202 462882271 501(C)(3) 109997 0 N/A N/A BETA CELL REGENERATION INDIANA UNIVERSITY PO BOX 66057 DETROIT MI 482780867 356001673 501(C)(3) 150000 0 N/A N/A PREVENTION INDIANA UNIVERSITY PO BOX 66057 INDIANAPOLIS IN 462666057 356001673 501(C)(3) 777404 0 N/A N/A BETA CELL REGENERATION INTEGRATED MEDICAL SENSORS INC 73 OVERBROOK IRVINE CA 92620 474751319 N/A 80000 0 N/A N/A ARTIFICIAL PANCREAS ITOLERANCE INC 1221 SHAFTER STREET SAN MATEO CA 94402 853086959 N/A 170000 0 N/A N/A BETA CELL REPLACEMENT JAEB CENTER FOR HEALTH RESEARCH 15310 AMBERLY DR STE 350 TAMPA FL 33647 593187624 501(C)(3) 332283 0 N/A N/A COMPLICATIONS JAEB CENTER FOR HEALTH RESEARCH 15310 AMBERLY DR STE 350 TAMPA FL 33647 593187624 501(C)(3) 204389 0 N/A N/A PREVENTION JOHNS HOPKINS UNIVERSITY 3400 N CHARLES STREET BALTIMORE MD 21218 520595110 501(C)(3) 350000 0 N/A N/A BETA CELL REPLACEMENT JOHNS HOPKINS UNIVERSITY 3400 N CHARLES STREET BALTIMORE MD 21218 520595110 501(C)(3) 198000 0 N/A N/A IMMUNOTHERAPIES JOSLIN DIABETES CENTER INC ONE JOSLIN PLACE BOSTON MA 02215 042203836 501(C)(3) 311228 0 N/A N/A BETA CELL REGENERATION JOSLIN DIABETES CENTER INC ONE JOSLIN PLACE BOSTON MA 02215 042203836 501(C)(3) 200000 0 N/A N/A BETA CELL REPLACEMENT MASSACHUSETTS GENERAL HOSPITAL 101 HUNTINGTON AVE 3RD FLOOR BOSTON MA 02199 042697983 501(C)(3) 196140 0 N/A N/A BETA CELL REGENERATION MASSACHUSETTS GENERAL HOSPITAL 101 HUNTINGTON AVE 3RD FLOOR BOSTON MA 02199 042697983 501(C)(3) 274164 0 N/A N/A BETA CELL REPLACEMENT MASSACHUSETTS GENERAL HOSPITAL 101 HUNTINGTON AVE 3RD FLOOR BOSTON MA 02199 042697983 501(C)(3) 100000 0 N/A N/A IMMUNOTHERAPIES MASSACHUSETTS GENERAL HOSPITAL 101 HUNTINGTON AVE 3RD FLOOR BOSTON MA 02199 042697983 501(C)(3) 65000 0 N/A N/A PSYCHOSOCIAL MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 65683 0 N/A N/A BETA CELL REPLACEMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 95000 0 N/A N/A METABOLIC CONTROL MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 559050001 416011702 501(C)(3) 200000 0 N/A N/A BETA CELL REGENERATION MILLIMAN 1301 5TH AVE STE 3800 SEATTLE WA 981012635 910675641 N/A 430000 0 N/A N/A TRANSPORTFOLIO NEURODON LLC 9800 CONNECTICUT DRIVE CROWN POINT IN 46307 465375254 N/A 184000 0 N/A N/A BETA CELL REGENERATION NEW YORK MEDICAL COLLEGE 40 SUNSHINE COTTAGE RD ADMINISTRATION BUILDING VALHALLA NY 10595 131099420 501(C)(3) 250000 0 N/A N/A BETA CELL REGENERATION NEW YORK STEM CELL FOUNDATION INC 619 WEST 54TH STREET 3RD FLOOR NEW YORK NY 10019 202905531 501(C)(3) 450000 0 N/A N/A BETA CELL REPLACEMENT NORTHWESTERN UNIVERSITY 633 CLARK ST - ROOM G-547 EVANSTON IL 60208 362167817 501(C)(3) 99978 0 N/A N/A COMPLICATIONS NORTHWESTERN UNIVERSITY 633 CLARK ST - ROOM G-547 EVANSTON IL 60208 362167817 501(C)(3) 220000 0 N/A N/A IMMUNOTHERAPIES OHIO UNIVERSITY 1 OHIO UNIVERSITY DRIVE ATHENS OH 45701 316402113 501(C)(3) 110000 0 N/A N/A BETA CELL REGENERATION OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND OR 97239 931176109 501(C)(3) 199598 0 N/A N/A ARTIFICIAL PANCREAS OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND OR 97239 931176109 501(C)(3) 25000 0 N/A N/A PSYCHOSOCIAL PHYSIOLOGIC DEVICES INC 2232 OLD STAGECOACH TRAIL ALPINE CA 91901 800917839 N/A 130000 0 N/A N/A ARTIFICIAL PANCREAS PRESIDENT AND FELLOWS OF HARVARD COLLEGE PO BOX 415649 BOSTON MA 022415649 042103580 501(C)(3) 6499999 0 N/A N/A BETA CELL REPLACEMENT QUAESTIO GLOBAL PARTNERS LLC ONE KNOLLWOOD TERRACE CHESTER NJ 07930 208396264 N/A 45000 0 N/A N/A IMMUNOTHERAPIES RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 546001796 501(C)(3) 212906 0 N/A N/A ARTIFICIAL PANCREAS RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 546001796 501(C)(3) 110000 0 N/A N/A BETA CELL REPLACEMENT RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 546001796 501(C)(3) 150000 0 N/A N/A IMMUNOTHERAPIES RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 546001796 501(C)(3) 300000 0 N/A N/A PREVENTION REGENTS OF THE UNIVERSITY OF COLORADO 1800 GRANT STREET 8TH FLOOR DENVER CO 80203 846000555 501(C)(3) 150000 0 N/A N/A ARTIFICIAL PANCREAS REGENTS OF THE UNIVERSITY OF COLORADO 1800 GRANT STREET 8TH FLOOR DENVER CO 80203 846000555 501(C)(3) 578994 0 N/A N/A COMPLICATIONS REGENTS OF THE UNIVERSITY OF COLORADO 1800 GRANT STREET 8TH FLOOR DENVER CO 80203 846000555 501(C)(3) 562623 0 N/A N/A IMMUNOTHERAPIES REGENTS OF THE UNIVERSITY OF COLORADO 1800 GRANT STREET 8TH FLOOR DENVER CO 80203 846000555 501(C)(3) 1204249 0 N/A N/A METABOLIC CONTROL REGENTS OF THE UNIVERSITY OF COLORADO 1800 GRANT STREET 8TH FLOOR DENVER CO 80203 846000555 501(C)(3) 1468624 0 N/A N/A PREVENTION REGENTS OF THE UNIVERSITY OF COLORADO 1800 GRANT STREET 8TH FLOOR DENVER CO 80203 846000555 501(C)(3) 150000 0 N/A N/A PSYCHOSOCIAL REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 S STATE STREET 5TH FLOOR WOLVERINE TOWER ANN ARBOR MI 48109 386006309 501(C)(3) 1578838 0 N/A N/A BETA CELL REPLACEMENT REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 S STATE STREET 5TH FLOOR WOLVERINE TOWER ANN ARBOR MI 48109 386006309 501(C)(3) 500000 0 N/A N/A COMPLICATIONS REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK ST SE MINNEAPOLIS MN 55455 416007513 501(C)(3) 348768 0 N/A N/A ARTIFICIAL PANCREAS REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK ST SE MINNEAPOLIS MN 55455 416007513 501(C)(3) 300000 0 N/A N/A BETA CELL REGENERATION RUTGERS THE STATE UNIVERSITY OF NEW JERSEY 33 KNIGHTSBRIDGE ROAD 2ND FLOOR EAST WING PISCATAWAY NJ 088543925 450583085 501(C)(3) 291509 0 N/A N/A PREVENTION SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 952160097 501(C)(3) 110000 0 N/A N/A BETA CELL REGENERATION SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 510197108 501(C)(3) 330000 0 N/A N/A BETA CELL REGENERATION STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 200000 0 N/A N/A ARTIFICIAL PANCREAS STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 64728 0 N/A N/A BETA CELL REGENERATION STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 66900 0 N/A N/A BETA CELL REPLACEMENT STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 399999 0 N/A N/A IMMUNOTHERAPIES STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 964998 0 N/A N/A METABOLIC CONTROL STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 150000 0 N/A N/A PSYCHOSOCIAL THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION INC 2000 LEVY AVENUE BUILDING A SUITE 351 TALLAHASSEE FL 32310 593211153 501(C)(3) 300000 0 N/A N/A PREVENTION THE LUNDQUIST INSTITUTE 1124 WEST CARSON ST TORRANCE CA 90502 952138184 501(C)(3) 1358963 0 N/A N/A MISSION THE METHODIST HOSPITAL RESEARCH INSTITUTE 6670 BERTNER AVE HOUSTON TX 77030 870721923 501(C)(3) 259699 0 N/A N/A BETA CELL REGENERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES PAYMENT SOLUTIONS AND COMPLIANCE BOX 957089 1125 MURPHY HALL 405 HIL LOS ANGELES CA 900957089 956006143 501(C)(3) 330000 0 N/A N/A BETA CELL REPLACEMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 941430692 946036493 501(C)(3) 500000 0 N/A N/A BETA CELL REGENERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 941430692 946036493 501(C)(3) 600000 0 N/A N/A BETA CELL REPLACEMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 941430692 946036493 501(C)(3) 1829999 0 N/A N/A IMMUNOTHERAPIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 941430692 946036493 501(C)(3) 199999 0 N/A N/A METABOLIC CONTROL THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 93524 0 N/A N/A IMMUNOTHERAPIES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE-SUITE 2200 CHAPEL HILL NC 275991350 566001393 501(C)(3) 95000 0 N/A N/A IMMUNOTHERAPIES TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK PO BOX 29789-GENERAL POST OFFICE NEW YORK NY 100879789 135598093 501(C)(3) 400000 0 N/A N/A ARTIFICIAL PANCREAS TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK PO BOX 29789-GENERAL POST OFFICE NEW YORK NY 100879789 135598093 501(C)(3) 110000 0 N/A N/A BETA CELL REGENERATION TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET FRANKLIN BUILDING 5TH FLOOR PHILADEPHIA PA 191046205 231352685 501(C)(3) 349999 0 N/A N/A BETA CELL REPLACEMENT TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET FRANKLIN BUILDING 5TH FLOOR PHILADELPHIA PA 191046205 231352685 501(C)(3) 66900 0 N/A N/A IMMUNOTHERAPIES TUFTS UNIVERSITY 419 BOSTON AVE MEDFORD MA 02155 042103634 501(C)(3) 100000 0 N/A N/A IMMUNOTHERAPIES UNITIO INC 11 AVENUE DE LAFAYETTE 5TH FLOOR BOSTON MA 02111 451623549 501(C)(3) 275000 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF ALABAMA AT BIRMINGHAM 1720 2ND AVE S AB 990 BIRMINGHAM AL 352940109 636005396 501(C)(3) 150000 0 N/A N/A BETA CELL REPLACEMENT UNIVERSITY OF CALIFORNIA DAVIS PO BOX 989062 WEST SACRAMENTO CA 957989062 946036494 501(C)(3) 150000 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE DEPT 0009 LA JOLLA CA 92093 956006144 501(C)(3) 266666 0 N/A N/A ARTIFICIAL PANCREAS UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE DEPT 0009 LA JOLLA CA 92093 956006144 501(C)(3) 343640 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE DEPT 0009 LA JOLLA CA 92093 956006144 501(C)(3) 307496 0 N/A N/A COMPLICATIONS UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE DEPT 0009 LA JOLLA CA 92093 956006144 501(C)(3) 504224 0 N/A N/A METABOLIC CONTROL UNIVERSITY OF FLORIDA 207 GRINTER HALL PO BOX 115500 GAINESVILLE FL 326115500 596002052 501(C)(3) 250000 0 N/A N/A BETA CELL REPLACEMENT UNIVERSITY OF FLORIDA 207 GRINTER HALL PO BOX 115500 GAINESVILLE FL 326115500 596002052 501(C)(3) 62958 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF FLORIDA 207 GRINTER HALL PO BOX 115500 GAINESVILLE FL 326115500 596002052 501(C)(3) 250000 0 N/A N/A PREVENTION UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC 3901 RAINBOW BLVD KANSAS CITY KS 661032937 481108830 501(C)(3) 110000 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF MIAMI 1320 S DIXIE HWY STE 760 212 PEARSON HALL CORAL GABLES FL 331462919 590624458 501(C)(3) 300000 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF MIAMI 1320 S DIXIE HWY STE 760 212 PEARSON HALL CORAL GABLES FL 331462919 590624458 501(C)(3) 307409 0 N/A N/A BETA CELL REPLACEMENT UNIVERSITY OF MIAMI 1320 S DIXIE HWY STE 760 212 PEARSON HALL CORAL GABLES FL 33146 590624458 501(C)(3) 269613 0 N/A N/A PREVENTION UNIVERSITY OF NOTRE DAME 836A GRACE HALL NOTRE DAME IN 46556 350868188 501(C)(3) 150000 0 N/A N/A METABOLIC CONTROL UNIVERSITY OF PITTSBURGH PO BOX 371220 PITTSBURGH PA 152517220 250965591 501(C)(3) 297291 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE ROOM 406 SALT LAKE CITY UT 84112 876000525 501(C)(3) 173377 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE ROOM 406 SALT LAKE CITY UT 84112 876000525 501(C)(3) 147269 0 N/A N/A METABOLIC CONTROL UNIVERSITY OF WASHINGTON 3917 UNIVERSITY WAY NE SEATTLE WA 98195 916001537 501(C)(3) 148232 0 N/A N/A PREVENTION UNIVERSITY OF WISCONSIN-MADISON UW-MADISON GAR ACCOUNT RESEARCH PROGRAMS-DRAWER 539 MILWAUKEE WI 53278 396006492 501(C)(3) 300000 0 N/A N/A BETA CELL REPLACEMENT UNIVERSITY OF WISCONSIN-MADISON UW-MADISON GAR ACCOUNT RESEARCH PROGRAMS-DRAWER 539 MILWAUKEE WI 53278 396006492 501(C)(3) 402655 0 N/A N/A COMPLICATIONS UT SOUTHWESTERN OFFICE OF POST AWARD ADMINISTRATION PO BOX 841765 DALLAS TX 752841765 752556007 501(C)(3) 600000 0 N/A N/A BETA CELL REGENERATION VANDERBILT UNIVERSITY PMB 407749 2301 VANDERBILT PLACE NASHVILLE TN 372407749 620476822 501(C)(3) 110000 0 N/A N/A METABOLIC CONTROL VANDERBILT UNIVERSITY MEDICAL CENTER (VUMC) PMB 407749 2301 VANDERBILT PLACE NASHVILLE TN 372407749 352528741 501(C)(3) 150000 0 N/A N/A METABOLIC CONTROL VTV THERAPEUTICS LLC 4170 MENDENHALL OAKS PARKWAY HIGH POINT NC 27265 352536301 N/A 130000 0 N/A N/A METABOLIC CONTROL WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 271570001 223849199 501(C)(3) 249999 0 N/A N/A BETA CELL REPLACEMENT WASHINGTON UNIVERSITY CAMPUS BOX 1034 700 ROSEDALE AVENUE ST LOUIS MO 631121408 430653611 501(C)(3) 214708 0 N/A N/A ARTIFICIAL PANCREAS WASHINGTON UNIVERSITY CAMPUS BOX 1034 700 ROSEDALE AVENUE ST LOUIS MO 631121408 430653611 501(C)(3) 94552 0 N/A N/A BETA CELL REPLACEMENT WASHINGTON UNIVERSITY CAMPUS BOX 1034 700 ROSEDALE AVENUE ST LOUIS MO 631121408 430653611 501(C)(3) 150000 0 N/A N/A PREVENTION WAYNE STATE UNIVERSITY 42 W WARREN AVE DETROIT MI 482023692 386028429 501(C)(3) 224166 0 N/A N/A METABOLIC CONTROL WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE BOX 89 NEW YORK NY 10065 131623978 501(C)(3) 249986 0 N/A N/A BETA CELL REPLACEMENT WILLIAM MARSH RICE UNIVERSITY 6100 MAIN STREET MS 16 HOUSTON TX 770051892 741109620 501(C)(3) 450000 0 N/A N/A BETA CELL REPLACEMENT YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 109998 0 N/A N/A BETA CELL REGENERATION YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 399344 0 N/A N/A IMMUNOTHERAPIES YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 110000 0 N/A N/A METABOLIC CONTROL YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 245472 0 N/A N/A PREVENTION 120 9 PART I, LINE 2: RESEARCH GRANTS ARE AWARDED BY JDRF INTERNATIONAL ("JDRFI") WITH THE SUPPORT OF JDRFI'S RESEARCH COMMITTEE COMPRISED OF "JDRF INTERNATIONAL BOARD MEMBERS AND OTHER VOLUNTEERS OR THE JDRF INTERNATIONAL BOARD OF DIRECTORS FOLLOWING THE RECOMMENDATIONS OF AN IN-HOUSE TEAM OF PROFESSIONAL SCIENTIFIC STAFF AND WITH INPUT FROM EXTERNAL SCIENTIFIC REVIEWERS. THE REVIEW PROCESS INCLUDES THE FOLLOWING CRITERIA: (1) THE SCIENTIFIC MERIT OF THE PROPOSED RESEARCH OUTLINED IN A GRANT APPLICATION AND (2) THE RELATIONSHIP OF THE PROPOSED RESEARCH TO JDRF'S GOAL TO IMPROVE LIVES TODAY AND TOMORROW BY ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D AND ITS COMPLICATIONS. THE SCIENTIFIC RESEARCH TEAM AND GRANT ADMINISTRATION STAFF MAINTAIN CLOSE CONTACT WITH GRANTEES, PROVIDING ADVICE AND EVALUATION, REVIEWING PROGRESS REPORTS, REVIEWING RESEARCH EXPENDITURES VERSUS AGREED BUDGETS, AND HELPING DISSEMINATE RESEARCH RESULTS. X 1 0 X X X X X 1 0 0 0 0 0 0 1 0 AARON KOWALSKI PHD CHIEF EXECUTIVE OFFICER 514382 0 162000 0 75000 0 26000 0 45994 0 823376 0 0 0 STEVEN ST PETER MANAGING DIRECTOR, T1D FUND 394125 0 318766 0 0 0 23201 0 14926 0 751018 0 0 0 TIMOTHY DOYLE COO/PRESIDENT/ASST TREAS (BEG 12/21) 434730 0 109300 0 0 0 21240 0 34860 0 600130 0 0 0 HELEN ELLIAS MANAGING DIRECTOR, T1D FUND 314474 0 215194 0 0 0 17876 0 45903 0 593447 0 0 0 TROY LINDLOFF CDO/ASST. TREASURER (END 11/21) 442235 0 0 0 57875 0 15582 0 2117 0 517809 0 0 0 CYNTHIA RICE CHIEF MISSION OFFICER 327838 0 20000 0 0 0 15690 0 24191 0 387719 0 0 0 JOANNE MARTZ CFO/TREASURER (END 5/21) 129955 0 0 0 218736 0 10833 0 13652 0 373176 0 0 0 SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 289769 0 56000 0 0 0 18140 0 2325 0 366234 0 0 0 GILLIAN GREEN VP LEADERSHIP GIVING 270511 0 33000 0 0 0 13943 0 33733 0 351187 0 0 0 CRAIG ROBERTSON VP, FIELD DEVELOPMENT 266233 0 44300 0 0 0 13693 0 17584 0 341810 0 0 0 YURY KUKUSHKIN MANAGING DIRECTOR, T1D FUND 220416 0 90215 0 0 0 13960 0 1223 0 325814 0 0 0 SYDNEY YOVIC CHIEF OF STAFF/ASSISTANT SECRETARY 215812 0 44000 0 0 0 12012 0 32399 0 304223 0 0 0 SRINIVAS MISHRA CHIEF TECH OFFICER (END 8/21) 245705 0 0 0 0 0 11367 0 16643 0 273715 0 0 0 ANNE GEHRING CONTRACT CFO (BEG 5/21, END 10/21) 174363 0 0 0 0 0 0 0 0 0 174363 0 0 0 PART I, LINE 1A HOUSING ALLOWANCE CEO AARON KOWALSKI RECEIVED A TAXABLE HOUSING ALLOWANCE AS PER THE TERMS OF HIS EMPLOYMENT AGREEMENT. THE TOTAL FOR FY 2022 WAS $75,000. PART I, LINE 4A SEVERANCE PAYMENTS JOANNE MARTZ AND TROY LINDLOFF BOTH RECEIVED SEVERANCE PAYMENTS AS PER THE TERMS OF THEIR EMPLOYMENT AGREEMENTS. THE TOTALS FOR BOTH ARE AS FOLLOWS: JOANNE MARTZ - $218,736 TROY LINDLOFF - $57,875 SEVERANCE PAYMENTS ARE REPORTED ON SCHEDULE J, PART II, COL. (B)(III) AS OTHER REPORTABLE COMPENSATION. SCHEDULE J, PART I, LINE 7 NON-FIXED PAYMENTS JDRF AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES' PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COL. (B) (II). STANTON BLACKWELL SEE BELOW 581287 SEE BELOW 0 E BEARD SEE BELOW 60386 SEE BELOW 0 SCHEDULE L, PART IV, LINE 1 (B) ANNE GEHRING WAS CONTRACT CFO AND THEREFORE TREASURER OF THE BOARD FOR SEVERAL MONTHS WHILE THE CFO VACANCY WAS FILLED. SHE IS A FOUNDING PARTNER OF STANTON BLACKWELL, A CONSULTING FIRM ENGAGED BY JDRF FOR VARIOUS ADVISORY SERVICES. (C) REPRESENTS NON-CFO SERVICES PAID BY JDRF.(D) JDRF PAID STANTON BLACKWELL FOR CONTRACT/INTERIM CFO SERVICES PERFORMED BY ANNE GEHRING, WHO IS A FOUNDING PARTNER OF STANTON BLACKWELL AND FOR OTHER NON-CEO ADVISORY SERVICES.(B) E. BEARD HAS A FAMILY RELATIONSHIP WITH GRANT BEARD, A MEMBER OF JDRF'S BOARD OF DIRECTORS.(D) EMPLOYMENT BY JDRF. X 278 5611770 NET PROCEEDS OF SALE 0 0 1 1 SCHEDULE M, PART I, LINE 32B THIRD PARTY ASSISTANCE CHARITABLE ADULT RIDES AND SERVICES (CARS) IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CALL A TOLL FREE NUMBER AND ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, CARS HANDLES ALL IRS 1098-C REPORTING. FOR THE YEAR ENDED 6/30/2022, CARS RAISED $186,460, WITH SELLING EXPENSES OF $20,763 AND FUNDRAISING SERVICE FEES OF $33,140. JDRF DOES NOT PAY CARS ANY EXPENSES OR FEES DIRECTLY. JDRF RECEIVED $132,557 OF NET REVENUE FROM CARS IN FY 2022. SCHEDULE M, PAGE 1 PART I, LINE 9 REPORTS THE NUMBER OF CONTRIBUTIONS OF SECURITIES THAT WERE MADE TO JDRF. FORM 990, PART I, LINE 1 AND PART III, LINE 1 - ORGANIZATION'S MISSION AT JDRF, WE WORK TIRELESSLY TO ACCELERATE BREAKTHROUGHS TO CURE, PREVENT AND TREAT TYPE 1 DIABETES (T1D). WE CONTINUALLY EXPAND OUR SCIENTIFIC KNOWLEDGE, OUR CONNECTIONS AND COLLABORATIONS, OUR PARTNERS AND GLOBAL PRESENCE TO UNLOCK THE SCIENCE THAT WILL STOP T1D. WHILE WE FIGHT FOR A CURE, WE STRIVE JUST AS HARD TO DEVELOP THERAPIES TO HELP PEOPLE RIGHT NOW. JDRF AND OUR SCIENTISTS ARE LEADING T1D RESEARCH AROUND THE WORLD. WE ADDRESS KEY GAPS TO MOVE RESEARCH FASTER AND FARTHER ACROSS THE DEVELOPMENT PIPELINE AND TO TRANSLATE BREAKTHROUGHS INTO NEW THERAPIES FOR PEOPLE WITH T1D. THIS ENABLES US TO ADVANCE SCIENCE WITH THE MOST POTENTIAL AND TO DRIVE RESEARCH THAT ATTRACTS MORE RESOURCES AND SCIENTIFIC EXPERTISE TO THE FIELD. WE INVEST IN THE EARLY STAGES, ALLOWING RESEARCHERS TO PURSUE INNOVATIVE IDEAS AND APPROACHES THAT WILL LEAD TO BREAKTHROUGH TREATMENTS. JDRF ALSO WORKS TO DRIVE NEW THERAPIES AND TECHNOLOGIES TO MARKET SO THEY GET INTO THE HANDS OF PEOPLE WITH T1D MORE QUICKLY. AND WE CONNECT THE T1D COMMUNITY TO CREATE A GLOBAL COMMUNITY OF SUPPORT FOR ANYONE AFFECTED BY T1D. FROM FUNDING INNOVATIVE RESEARCH TO ADVOCATING FOR GOVERNMENT ACTION AND PROVIDING A SUPPORT STRUCTURE FOR OUR COMMUNITY, NO OTHER ORGANIZATION DOES MORE TO FIGHT T1D THAN JDRF. SINCE OUR FOUNDING, JDRF HAS FUNDED MORE THAN $2.1 BILLION IN RESEARCH AND HAS MADE SIGNIFICANT PROGRESS IN UNDERSTANDING AND FIGHTING THE DISEASE. OUR ACTIONS - THROUGH ADVOCACY AND OUR OWN INVESTMENTS IN T1D RESEARCH - INFLUENCE OTHER ORGANIZATIONS, CORPORATIONS AND GOVERNMENT AGENCIES TO FOLLOW OUR LEAD AND DIRECT ADDITIONAL FUNDING TOWARD T1D RESEARCH. TODAY, EVERY $1 JDRF INVESTS IN RESEARCH ATTRACTS AN ADDITIONAL $7.42 TO THE FIELD. FOR FISCAL YEAR 2022, JDRF'S APPROXIMATELY $97 MILLION IN DIRECT FUNDING ATTRACTED $375 MILLION IN ADDITIONAL INVESTMENT IN T1D RESEARCH FROM U.S. AND INTERNATIONAL GOVERNMENT, NGOS AND CHARITABLE ORGANIZATIONS, AND CORPORATE PARTNERS. FORM 990, PART III, LINE 4A: RESEARCH GRANTS JDRF HAS PLAYED A SIGNIFICANT ROLE IN NEARLY EVERY T1D ADVANCEMENT--DRUG, DEVICE, CELL THERAPY--MADE IN THE LAST 50 YEARS. OUR FUNDING SUPPORTS MORE THAN 330 ACTIVE T1D RESEARCH GRANTS IN THE UNITED STATES AND 21 OTHER COUNTRIES AROUND THE WORLD, INCLUDING MORE THAN 160 GRANTS IN FY2022 ALONE, PLUS 66 CLINICAL TRIALS. WE LEVERAGE PARTNERSHIPS WITH ACADEMIA, INDUSTRY, AND CLINICIANS TO ACCELERATE THE MOST PROMISING RESEARCH OPPORTUNITIES. OUR HIGHEST PRIORITY IS DEVELOPING CURES FOR T1D AND IMPROVING LIVES OF THOSE LIVING WITH THE DISEASE TODAY, INCLUDING RESEARCH IN GLUCOSE CONTROL AND PREVENTION OF T1D COMPLICATIONS. THE FULL IMPACT OF JDRF'S RESEARCH INVESTMENT EXTENDS WELL BEYOND DIRECT FUNDING. THROUGH ADVOCACY AND INFLUENCE, JDRF DRIVES FUNDING FROM OTHER SOURCES INTO T1D RESEARCH AND HAS HELPED SECURE PASSAGE OF THE SPECIAL DIABETES PROGRAM, PUTTING MORE THAN $3 BILLION IN FEDERAL FUNDING TOWARD T1D RESEARCH OVER THE LAST TWO DECADES. IN ADDITION, JDRF FOUNDED THE JDRF T1D FUND (WWW.T1DFUND.ORG). A WHOLLY OWNED ENTITY OF JDRF, THE T1D FUND IS A VENTURE PHILANTHROPY FUND ACCELERATING LIFE-CHANGING SOLUTIONS TO TREAT, PREVENT, AND CURE T1D THROUGH CATALYTIC COMMERCIAL INVESTMENTS. THROUGH ITS INVESTMENTS IN PARTNERSHIP WITH PRIVATE CAPITAL, INCLUDING VENTURE CAPITAL, PHARMA, AND FOUNDATIONS, THE T1D FUND SEEKS TO ATTRACT THE PRIVATE INVESTMENT NECESSARY TO ADVANCE DRUGS, DEVICES, DIAGNOSTICS, AND VACCINES TO HELP PEOPLE LIVING WITH T1D AND THOSE WHO ARE AT RISK OF DEVELOPING THE DISEASE. THE T1D FUND INVESTS IN OPPORTUNITIES THAT DRIVE OUR MISSION, WITH AN EXCLUSIVE FOCUS ON THE MOST PROMISING COMMERCIAL OPPORTUNITIES. ALL FUNDS GO DIRECTLY TO SUPPORT COMPANIES DEVELOPING APPROACHES TO TREAT, PREVENT, AND CURE T1D. IN ACCORDANCE WITH GAAP, $11.8 MM OF THE T1D FUND'S TOTAL INVESTMENTS AS OF JUNE 30, 2022, ARE REFLECTED IN THE BALANCE SHEET (PART X) AND NOT INCLUDED WITHIN THE ORGANIZATION'S RESEARCH - RELATED MISSION EXPENSE. THE FOUNDATION'S DIVERSIFIED RESEARCH PORTFOLIO INCLUDES A FOCUS ON CURING T1D AND IMPROVING LIVES. CURING T1D WE FACE TWO KEY CHALLENGES IN CURING T1D. WE MUST PREVENT, STOP, OR REVERSE THE (1) LOSS OF INSULIN-PRODUCING BETA CELLS AND (2) THE IMMUNE SYSTEM'S ATTACK ON BETA CELLS. JDRF IS ACCELERATING OUR WORK IN CURING T1D BY FOCUSING ON THREE AREAS THAT HAVE ADVANCED DRAMATICALLY OVER THE YEARS: SCREENING FOR RISK OF T1D, CELL THERAPIES, AND DISEASE-MODIFYING THERAPIES. SCREENING FOR RISK OF T1D: FOCUS ON EXPANDING SCREENING FOR T1D-RELATED AUTOANTIBODIES AND SCREENING AWARENESS. DONOR-FUNDED RESEARCH HAS DISCOVERED THAT HAVING TWO OR MORE T1D-SPECIFIC ANTIBODIES MEANS THAT YOU HAVE AN ALMOST 100% CHANCE OF DEVELOPING DIABETES IN YOUR LIFETIME. WITH ONE BLOOD TEST, YOU CAN FIND OUT--BEFORE SYMPTOMS APPEAR--IF YOU ARE AT RISK. THIS CAN REDUCE THE RISK OF DIABETIC KETOACIDOSIS AND HOPITALIZATION AT THE ONSET OF SYMPTOMS AND IDENTIFY PEOPLE WHO CAN TAKE PART IN CLINICAL TRIALS TO DELAY OR PREVENT T1D. CELL THERAPIES: FOCUS ON REPLACING INSULIN-PRODUCING BETA CELLS FROM OUTSIDE SOURCES SUCH AS STEM CELLS OR NON-HUMAN CELLS. THROUGH DONOR-FUNDED RESEARCH, WE NOW KNOW THAT WHEN SOMEONE HAS T1D, THEIR OWN BODY BEGINS ATTACKING AND DESTROYING THE BETA CELLS THAT CREATE INSULIN. IF WE CAN SAVE OR REPLACE BETA CELLS, WE CAN HELP CURE T1D. THERE IS EARLY BUT CRUCIAL PROGRESS SEEN IN RECENTLY REPORTED CLINICAL TRIALS WHERE BETA CELL REPLACEMENT HAS MADE ADVANCES TOWARD INSULIN INDEPENDENCE, BETTER T1D CONTROL, AND LONGEVITY OF THE THERAPIES. DISEASE-MODIFYING THERAPIES: FOCUS ON WAYS TO KEEP THE IMMUNE SYSTEM FROM ATTACKING AND DESTROYING BETA CELLS, WAYS TO PROTECT AND SPUR THEM, AND DEVELOP TREATMENTS THAT CAN SLOW, HALT, OR REVERSE T1D, AT ANY AGE OR STAGE OF THE DISEASE. RESEARCH HAS SHOWN THAT IMMUNE THERAPIES CAN INTERACT WITH A PERSON'S IMMUNE SYSTEM, TRAINING IT TO COMBAT INTERNAL BATTLES THAT LEAD TO THE DESTRUCTION OF ITS OWN BETA CELLS. WHILE T1D REMAINS ONE OF THE FEW MAJOR AUTOIMMUNE DISEASES WITHOUT AN EFFECTIVE DRUG THERAPY TO CHANGE THE COURSE OF THE DISEASE, WE KNOW WE ARE GETTING CLOSE. IMPROVING LIVES T1D BRINGS WITH IT DAILY STRUGGLES AND STRESSES THAT THAT MAKE THE CHALLENGES OF LIVING A HEALTHY AND LONG LIFE WITH T1D VERY REAL. JDRF FIGHTS EVERY DAY TO ADVANCE RESEARCH THAT CAN REDUCE THE BURDEN OF LIVING WITH T1D AND KEEP PEOPLE AS HEALTHY AS POSSIBLE UNTIL WE FIND CURES. SPECIFICALLY, WE ARE STRIVING TO IMPROVE LIVES BY ACCELERATING THE DEVELOPMENT OF DRUGS, DEVICES, BEHAVIORAL HEALTH INTERVENTIONS, AND COMBINATIONS OF THESE, TO IMPROVE SHORT- AND LONG-TERM HEALTH OUTCOMES AND QUALITY OF LIFE, THROUGH THE FOLLOWING THREE PROGRAMS. GLUCOSE CONTROL: FOCUS ON HELPING THOSE WITH T1D MANAGE GLUCOSE LEVELS AND OVERALL METABOLIC BALANCE, INCLUDING IMPROVED ARTIFICIAL PANCREAS TECHNOLOGY, DEVELOPING NEXT-GENERATION INSULINS, AND DEVELOPING NEW DRUGS THAT CONTROL GLUCOSE AND OTHER METABOLIC FACTORS IN NOVEL WAYS. WE KNOW THAT FEWER THAN 30% OF PEOPLE WITH T1D IN THE U.S. CONSISTENTLY MAINTAIN TARGET BLOOD-GLUCOSE LEVELS--MEANING THAT 70% ARE AT RISK OF SERIOUS HEALTH ISSUES. AIMING TO ENSURE OUR COMMUNITY IS HEALTHY WHEN CURES ARE FOUND, WE WILL CONTINUE TO FOCUS ON NOVEL INSULINS, ADJUNCTIVE THERAPIES IN ADDITION TO INSULIN THAT MAKE IT EASIER TO LIVE WITH T1D, AND SMALLER, EASIER TO WEAR INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORS WITH IMPROVED ALGORITHMS THAT SHOULDER MORE OF THE BURDEN OF T1D. COMPLICATIONS: FOCUS ON ACCELERATING THERAPIES THAT PREVENT AND TREAT KIDNEY AND EYE DISEASE. WE KNOW THAT MORE THAN 90% OF PEOPLE WITH T1D DEVELOP SOME LEVEL OF EYE DISEASE WITHIN 20 YEARS OF DIAGNOSIS AND THAT 1 IN 4 DEVELOP KIDNEY DISEASE. JDRF WILL DIRECT FUNDS TO DEVELOP AND IMPROVE EYE AND KIDNEY DISEASE TREATMENTS, SO THAT PEOPLE AT RISK CAN TAKE STEPS TO INTERVENE EARLY IN THE DISEASE PROCESS. PSYCHOSOCIAL HEALTH: FOCUS ON REDUCING THE PSYCHOSOCIAL CHALLENGES OF T1D. EARLY RESEARCH HAS SHOWN THAT THE BURDEN OF LIVING WITH T1D TAKES A TOLL BEYOND THE PHYSICAL COMPLICATIONS, OFTEN AFFECTING PEOPLE'S SOCIAL, BEHAVIORAL, AND EMOTIONAL WELL-BEING, KNOWN COLLECTIVELY AS PSYCHOSOCIAL HEALTH. WE AIM TO REDUCE THE CHALLENGES THROUGH INCREASING THE NUMBER OF AND PROVIDING ACCESS TO PSYCHOLOGISTS TRAINED IN T1D, SUPPORTING RESEARCH INITIATIVES TO IMPROVE PSYCHOSOCIAL HEALTH AND OUTCOMES, AND EDUCATING THE T1D COMMUNITY ABOUT THE PSYCHOSOCIAL IMPACT OF THE DISEASE. FORM 990, PART III, LINE 4B: RESEARCH SUPPORT JDRF'S IN-HOUSE TEAM OF SKILLED AND CREDENTIALED SCIENTIFIC, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS PLAYS A CRITICAL ROLE IN LEADING AND SUPPORTING THE RESEARCH STRATEGY AND DISTRIBUTION OF RESEARCH FUNDS FROM JDRF--AND OUR PARTNER ORGANIZATIONS--TOWARD CREATING A WORLD WITHOUT T1D. OUR PROFESSIONALS IDENTIFY, EVALUATE, AND INFLUENCE GROUNDBREAKING RESEARCH FOR FUNDING AND WORK WITH OTHER FOUNDATIONS, GOVERNMENTS, AND INDUSTRY PARTNERS TO ACCELERATE THE MISSION WE ALL SHARE. JDRF PROFESSIONALS WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE RESEARCH CAN PROCEED WITHOUT DELAY AND THAT ADVANCES ARE WELL UNDERSTOOD BY HEALTHCARE DECISION MAKERS. AS PART OF THESE EFFORTS, JDRF ORGANIZES AND FUNDS SCIENTIFIC MEETINGS, SYMPOSIA, AND CONFERENCES, TO ENSURE THAT JDRF'S RESEARCH STRATEGY IS ALIGNED WITH THE NEEDS OF THE T1D COMMUNITY AND ALLOW JDRF TO PROVIDE SCIENTIFIC UPDATES ON THE RESEARCH IT MANAGES. THIS EFFORT ENSURES THAT ALL THE RESEARCH IS CONTINUALLY SHARED AND BUILT UPON BY T1D RESEARCHERS AROUND THE GLOBE. THE STRATEGIC ADVISORY PANEL (SAP) IS COMPOSED OF FIVE ESTABLISHED T1D EXPERTS IN VARIOUS ASPECTS OF THE FIELD, INCLUDING PEDIATRIC ENDOCRINOLOGY, PREVENTION, AND TREATMENT OF T1D, IMMUNOTHERAPIES, REGULATORY, AND DRUG DEVELOPMENT. THE SAP CONTRIBUTES TO JDRF SCIENTISTS' STRATEGIC PLANNING AROUND RESEARCH FUNDING GOALS AND PRIORITIES. JDRF'S WORK TO BRING TOGETHER THE BEST MINDS IN THE FIELD ENHANCES JDRF'S ABILITY TO FORECAST FUTURE SCIENTIFIC DIRECTION, JUDGE THE POTENTIAL EFFECTIVENESS OF NEW PATHWAYS, AND IDENTIFY GAPS WHERE JDRF FUNDING CAN MAKE THE MOST IMPACT. FORM 990, PART III, LINE 4C: PUBLIC EDUCATION JDRF IS UNIQUELY QUALIFIED TO PROVIDE PUBLIC EDUCATION ABOUT DIABETES AND ITS COMPLICATIONS. JDRF'S EFFORTS IMPACT NOT ONLY THE MILLIONS OF PEOPLE LIVING WITH T1D, THEIR FAMILIES, AND THE GENERAL PUBLIC, BUT ALSO THOSE AT RISK FOR DEVELOPING THE DISEASE. T1D STRIKES BOTH CHILDREN AND ADULTS, AND THE CRITICAL ADJUSTMENT PERIOD FOLLOWING A DIAGNOSIS CAN BE OVERWHELMING. THAT'S WHY WE SUPPORT FAMILIES NAVIGATING THIS CHALLENGING TIME. JDRF ALSO EDUCATES PEOPLE ABOUT THE WARNING SIGNS OF T1D, AIMED AT ENSURING TIMELY DIAGNOSES AND REDUCING THE POTENTIAL CATASTROPHIC CONSEQUENCES OF UNDIAGNOSED T1D. JDRF ALSO PROVIDES INFORMATION AND UPDATES ABOUT CURRENT RESEARCH DIRECTIONS AND PROGRESS AND ABOUT HUMAN CLINICAL TRIALS THAT ARE SEEKING PARTICIPANTS (INCLUDING THROUGH JDRF'S CLINICAL TRIALS CONNECTION MATCHING TOOL: WWW.JDRF.ORG/RESEARCH/CLINICAL-TRIALS). THROUGH ALL OF OUR NATIONAL U.S. CHAPTERS; FIVE INTERNATIONAL AFFILIATES IN AUSTRALIA, CANADA, ISRAEL, THE NETHERLANDS, AND UNITED KINGDOM; THE 30,000 MEMBERS OF OUR SOCIAL NETWORK, TYPEONENATION; AND MORE THAN ONE MILLION SUPPORTERS, JDRF FIGHTS TO MEET THE T1D COMMUNITY'S DIVERSE NEEDS, CONNECTING PEOPLE WITH LOCAL SUPPORT, EXPERT RESOURCES, AND THE GLOBAL EFFORT TO CREATE A WORLD WITHOUT T1D. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW PROCESS JDRF HAS A RIGOROUS STANDARD APPROACH TO REVIEWING ITS 990. THE ORGANIZATION'S ACCOUNTING MANAGER WORKS WITH ITS OUTSIDE TAX PREPARERS TO PREPARE THE RETURN AND ALL SUPPORTING SCHEDULES. THE DRAFT RETURN IS REVIEWED BY A NUMBER OF INDIVIDUALS, INCLUDING JDRF'S CHIEF FINANCIAL OFFICER, OTHER EXECUTIVES, ITS EXTERNAL SENIOR TAX ADVISOR AND OTHERS AS NECESSARY TO ENSURE ACCURACY. ANY QUESTIONS AND CHANGES WITH RESPECT TO THE DRAFT RETURNS ARE ADDRESSED. FOLLOWING THIS PROCESS, THE RETURN IS REVIEWED BY JDRF'S AUDIT AND RISK COMMITTEE OF THE BOARD OF DIRECTORS WITH ITS OUTSIDE TAX ADVISORS. ONCE APPROVED, THE RETURN IS DISTRIBUTED TO ALL MEMBERS OF JDRF'S BOARD OF DIRECTORS FOR REVIEW AND COMMENT BEFORE IT IS FILED WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C COVERED PERSONS COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM AND ACKNOWLEDGE THE JDRF CODE OF ETHICS AT THE BEGINNING OF EACH FISCAL YEAR. COVERED PERSONS INCLUDE: MEMBERS OF THE INTERNATIONAL BOARD OF DIRECTORS, DIRECTORS EMERITUS, MEMBERS OF THE GLOBAL MISSION BOARD, CHAPTER DIRECTORS AND OFFICERS, DIRECTORS OF THE JDRF T1D FUND, AND MEMBERS OF THE T1D FUND INVESTMENT COMMITTEE. WHEN A CONFLICT IS DISCLOSED, THE COVERED PERSON SHALL ABSTAIN FROM PARTICIPATING IN DECISIONS AND/OR DISCUSSIONS INVOLVING JDRF'S BUSINESS OR RELATIONSHIP WITH THE RELEVANT THIRD PARTY. IF THE COVERED PERSON IS ASKED TO ABSTAIN, THE COVERED PERSON MAY STILL BE PERMITTED TO STATE HIS OR HER POSITION ON SUCH MATTER AND TO ANSWER PERTINENT QUESTIONS AND INQUIRIES RELATING THERETO. THE COVERED PERSON MAY BE ASKED TO LEAVE THE MEETING DURING THE DISCUSSION OF AND/OR VOTE ON THE MATTER INVOLVING THE RELEVANT THIRD PARTY. FORM 990, PART VI, SECTION B, LINE 15 EXECUTIVE COMPENSATION POLICY JDRF'S BOARD OF DIRECTORS CHARGES A TALENT AND COMPENSATION COMMITTEE TO DEVELOP AND RECOMMEND A COMPENSATION PHILOSOPHY THAT APPLIES TO ALL EMPLOYEES OF JDRF, INCLUDING RECOMMENDATIONS REGARDING THE COMPENSATION AND BENEFITS OF JDRF SENIOR MANAGEMENT FOR APPROVAL BY THE BOARD OF DIRECTORS. THE COMMITTEE WORKS IN COLLABORATION WITH THE PRESIDENT AND CEO AND THE CHIEF HUMAN RESOURCES OFFICER AND OTHER SENIOR STAFF PERSONNEL IN THE JDRF HUMAN RESOURCES DEPARTMENT TO ENSURE THAT 1) THE FOUNDATION'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) JDRF IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR JDRF'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. TO ATTRACT AND RETAIN TOP SCIENTIFIC AND EXECUTIVE TALENT TO ADVANCE ITS MISSION, THE ORGANIZATION PAYS COMPETITIVE AND APPROPRIATE SALARIES AS DETERMINED BY ANALYSIS OF RELIABLE DATA AND INPUT FROM INDEPENDENT THIRD-PARTY CONSULTANTS. THE REVIEW OF JDRF EXECUTIVE COMPENSATION AND BENEFITS UNDER THE PROCEDURES NOTED ABOVE IS COMPLETED ANNUALLY BY AN INDEPENDENT COMPENSATION COMMITTEE, AND THE BASIS FOR THEIR DETERMINATION IS DOCUMENTED CONTEMPORANEOUSLY IN THE MINUTES OF THE COMMITTEE'S MEETINGS, INCLUDING MOST RECENTLY ON JUNE 30, 2022. FORM 990, PART VI, SECTION C, LINE 19 PUBLIC DOCUMENTS THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE: WWW.JDRF.ORG. THE PUBLIC MAY ACCESS COPIES OF JDRF'S W-9, ANNUAL REPORTS, 990 TAX RETURNS, 501(C)(3) IRS LETTER, AND AUDITED FINANCIALS, AT THE FOLLOWING LINK: WWW.JDRF.ORG/ABOUT/FINANCIALS. JDRF T1D FUND LLC C/O JDRF - 200 VESEY ST 28TH FL NEW YORK NY 10281 274967989 FUNDR/INVEST DE 5969622 163269000 JDRF SCHEDULE R, PART I, LINE (1B) THE PRIMARY ACTIVITY FOR THE JDRF T1D FUND IS FUNDRAISING AND INVESTING IN TYPE ONE DIABETES RESEARCH. PLEASE SEE DETAILED DESCRIPTION ON SCHEDULE O, PART III, LINE 4A, STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS FOR RESEARCH GRANTS.